INS and type 2 diabetes mellitus: In a recent market research survey of patients with type 1 and type 2 diabetes, approximately 66% of respondents reported that they would switch to a hypothetical less expensive biosimilar insulin recommended by their provider [22], yet their most common concern was whether the biosimilar product would be as safe and effective as the reference product.